Carregant...
The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy
Anti-VEGF-A therapy has become a mainstay of treatment for ocular neovascularisation and in cancer; however, their effectiveness is not universal, in some cases only benefiting a minority of patients. Anti-VEGF-A therapies bind and block both pro-angiogenic VEGF-A(xxx) and the partial agonist VEGF-A...
Guardat en:
| Publicat a: | Angiogenesis |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Netherlands
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4280485/ https://ncbi.nlm.nih.gov/pubmed/25274272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-014-9444-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|